TCR2 Therapeutics up on promising data from cancer therapy

TCR2 Therapeutics

28/09/2022 13:19

** TCR2 Therapeutics Inc's shares  TCRR.O  rise 11.8% to
$1.89 before the bell 
    ** Co says its cell therapy to treat solid tumor including
ovarian Cancer and Mesothelioma demonstrates tolerability and
clinical benefit in the early-stage study  urn:newsml:reuters.com:*:nGNX4f2Byp 
    ** Near-term opportunity is to further improve clinical
benefit of the therapy by using it in combination with type of
immunotherapy and redosing strategies in mid-stage study - TCRR
    ** Mesothelioma is cancer of the thin tissue, mesothelium,
that lines the lung, chest wall, and abdomen
    ** Up to Tuesday's close, stock down ~64% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))